Serum test identifies patients deriving benefit from CPIs 203 5 Supplementary Table S17: Power to detect effect size observed in the development set in validation set 2. PFS OS Comparison Classifications predicted Classifications assigned Classifications predicted Classifications assigned Resistant vs. intermediate 49% 45% 40% 36% Intermediate vs. sensitive 47% 43% 52% 47% Resistant vs. sensitive 97% 98% 96% 98% Resistant vs. not resistant 89% 91% 86% 88% Sensitive vs. not sensitive 87% 87% 87% 87% iii. Chemotherapy Cohort (n=68) The expected number of patients of each classification group given development set data are 24 resistant, 25 intermediate and 19 sensitive. On running the test on the samples of the chemotherapy cohort, 18 samples were classified as resistant, 21 as intermediate and 29 as sensitive. Supplementary Table S18: Power to detect effect size observed in the development set in the chemotherapy cohort. PFS OS Comparison Classifications predicted Classifications assigned Classifications predicted Classifications assigned Resistant vs. intermediate 46% 38% 37% 30% Intermediate vs. sensitive 43% 48% 48% 53% Resistant vs. sensitive 95% 96% 94% 95% Resistant vs. not resistant 86% 81% 82% 76% Sensitive vs. not sensitive 84% 90% 84% 90%
RkJQdWJsaXNoZXIy MTk4NDMw